Sonoscape Medical Corp. Hits Day Low at CNY 23.23 Amid Price Pressure

Sonoscape Medical Corp., a large-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline today, with the stock dropping 5.9% as of March 23, 2026. The stock reached an intraday low of CNY 23.23, reflecting ongoing challenges in its financial performance. Over the past week, Sonoscape has seen a decrease of 9.05%, and its one-month performance shows a decline of 11.92%. Year-to-date, the stock is down 11.32%, significantly underperforming the China Shanghai Composite, which has seen a decline of only 3.92% during the same period. In terms of financial metrics, Sonoscape's net profit for the first nine months has decreased by 68.17%, while its operating cash flow has reached a low of CNY -98.58 million. The company's return on equity stands at 0.57%, and it has a high price-to-book ratio of 4.72, indicating a potentially expensive valuation. With a dividend yield of 0.38%, the stock continues to face scrutiny as it navigates a challenging market landscape.